Vitamin E, including its beta and delta tocopherol forms, has been investigated for its potential role in supporting or treating Age-related Macular Degeneration (AMD). The primary scientific rationale stems from Vitamin E's antioxidant properties, which may help protect retinal cells from oxidative stress—a key factor in AMD pathogenesis. However, most clinical research has focused on alpha-tocopherol, the most biologically active form of Vitamin E, rather than beta or delta tocopherols specifically.

The largest and most influential study in this area is the Age-Related Eye Disease Study (AREDS and AREDS2), which evaluated the effects of high-dose antioxidant supplementation (including Vitamin E, but as alpha-tocopherol, not beta/delta forms) on AMD progression. AREDS found that the combination of antioxidants (Vitamin C, Vitamin E, beta-carotene, zinc, and copper) modestly reduced the risk of progression to advanced AMD in high-risk individuals. However, the study did not isolate the effects of Vitamin E alone, nor did it investigate beta or delta tocopherols specifically.

Overall, while there is modest scientific evidence supporting the use of antioxidant vitamins (including Vitamin E) in slowing AMD progression, this evidence does not specifically pertain to beta or delta tocopherol forms. Thus, the evidence for beta and delta tocopherols in AMD is weak and largely extrapolated from data on alpha-tocopherol.